Drug Profile
Research programme: cancer vaccines - Altimmune
Alternative Names: Adjusyn; OncosynLatest Information Update: 23 Mar 2023
Price :
$50
*
At a glance
- Originator Immune Targeting Systems
- Developer Altimmune
- Class Cancer vaccines
- Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer